In this interview, Bodo Knudsen, MD, outlines his step-by-process for obtaining percutaneous access, discusses the ways he reduces radiation exposure during PCNL, and gives his thoughts on how clinicians can gain proficiency with access.
The largest analysis of active surveillance for metastatic renal cell carcinoma presented to date shows that a proportion of patients can be safely observed without need to start systemic therapy right away.
This is a post-only, outbound email. Please do not reply to this email as we will be unable to respond to your reply. Please use the links provided if you have questions or concerns regarding this email or your subscription.
This email was sent by: MultiMedia Healthcare
535 Connecticut Avenue, Suite 300
Norwalk, CT, 06854, USA